Rom Paz

TL;DR: A new type of GSK-3 inhibitor, L807mts, is described that acts through a substrate-to-inhibitor conversion mechanism that occurs within the catalytic site of the enzyme.

TL;DR: This study shows that inhibition of mTORC1 and increased autophagic activity are downstream to GSK-3 inhibition and contribute to lysosomal acidification, and finds that the tuberous sclerosis complex, TSC, is required forLysosome acidification and is activated by GSK -3 inhibition.

TL;DR: In this paper , the potential of TTFields concomitant with anti- PD-1/anti-cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA-4) or anti-programmed deathligand 1 (antiPD-L1) immune checkpoint inhibitors (ICI) to improve therapeutic efficacy was examined in lung tumor-bearing mice.

TL;DR: TTFields therapy displays a novel immunoregulatory role in macrophage polarization and promotes a pro-inflammatory phenotype in Macrophages in mice treated with glioblastoma or mesothelioma.

TL;DR: Permeability of 4T1 breast cancer cells was elevated by TTFields, allowing enhanced intracellular accumulation of DOX and improving drug efficacy, even in chemotherapy-resistant cells.